Abstract | BACKGROUND: Prophylactic tocolysis with betamimetics and other agents has become widespread as a treatment for fetal distress. Uterine relaxation may improve placental blood flow and therefore fetal oxygenation. However there may also be adverse maternal cardiovascular effects. OBJECTIVES: SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth Group trials register and the Cochrane Controlled Trials Register. Date of last search: February 1999. SELECTION CRITERIA: DATA COLLECTION AND ANALYSIS: Two reviewers assessed trial quality and extracted data. MAIN RESULTS: Three studies were included. Compared with no treatment, there were fewer failed improvements in fetal heart rate abnormalities with tocolytic therapy (relative risk 0.26, 95% 0.13 to 0.53). Betamimetic therapy compared with magnesium sulphate showed a non-significant trend towards reduced uterine activity (relative risk 0.07, 95% confidence interval 0.00 to 1.10). REVIEWER'S CONCLUSIONS: Betamimetic therapy appears to be able to reduce the number of fetal heart rate abnormalities and perhaps reduce uterine activity. However there is not enough evidence based on clinically important outcomes to evaluate the use of betamimetics for suspected fetal distress.
|
Authors | R Kulier, G J Hofmeyr |
Journal | The Cochrane database of systematic reviews
(Cochrane Database Syst Rev)
Issue 2
Pg. CD000035
( 2000)
ISSN: 1469-493X [Electronic] England |
PMID | 10796094
(Publication Type: Journal Article, Review, Systematic Review)
|
Chemical References |
- Tocolytic Agents
- Magnesium Sulfate
- Hexoprenaline
- Terbutaline
|
Topics |
- Female
- Fetal Distress
(drug therapy)
- Hexoprenaline
(therapeutic use)
- Humans
- Magnesium Sulfate
(therapeutic use)
- Obstetric Labor Complications
(drug therapy)
- Pregnancy
- Terbutaline
(therapeutic use)
- Tocolytic Agents
(therapeutic use)
|